tiprankstipranks
Trending News
More News >
STELLA PHARMA CORPORATION (JP:4888)
:4888
Japanese Market

STELLA PHARMA CORPORATION (4888) AI Stock Analysis

Compare
0 Followers

Top Page

JP

STELLA PHARMA CORPORATION

(4888)

Rating:55Neutral
Price Target:
¥406.00
▲(5.45%Upside)
The stock score reflects strong revenue growth and solid equity, balanced by operational losses and negative profit margins. Technical indicators suggest a mixed outlook with potential for upward movement. Valuation remains a concern due to negative earnings and lack of dividends.

STELLA PHARMA CORPORATION (4888) vs. iShares MSCI Japan ETF (EWJ)

STELLA PHARMA CORPORATION Business Overview & Revenue Model

Company DescriptionSTELLA PHARMA CORPORATION (4888) is a pharmaceutical company that specializes in the research, development, and commercialization of innovative medical treatments. Operating within the healthcare sector, the company focuses primarily on oncology, providing advanced therapeutics aimed at improving patient outcomes and quality of life. Its core products include a range of proprietary drugs and treatment solutions designed to address various forms of cancer.
How the Company Makes MoneySTELLA PHARMA CORPORATION makes money through the sale of its pharmaceutical products, particularly in the oncology space. The company's revenue model primarily relies on the development and commercialization of proprietary drugs that are sold to healthcare providers, hospitals, and clinics. Revenue streams are bolstered by partnerships with other pharmaceutical companies and research institutions, which can include licensing agreements, joint ventures, and collaborative research projects. Additionally, the company may generate income from royalties on licensed technologies and products as well as government grants for research and development in therapeutic areas.

STELLA PHARMA CORPORATION Financial Statement Overview

Summary
STELLA PHARMA CORPORATION has shown impressive revenue growth and a strong equity base, which are positive indicators. However, the persistent operational losses and negative profit margins are significant concerns. The shift to positive free cash flow suggests potential for improved financial health if operational efficiencies can be achieved.
Income Statement
45
Neutral
The company has shown significant revenue growth over the years, with a remarkable increase from ¥100 million in 2022 to ¥961 million in 2025. However, the company is not profitable yet, as it continues to report negative net income and EBIT. Profit margins are negative, which is a concern as it indicates ongoing operational challenges.
Balance Sheet
70
Positive
The balance sheet shows a strong equity position with Stockholders' Equity consistently higher than Total Debt, resulting in a low Debt-to-Equity ratio. The equity ratio is robust, reflecting a stable financial structure. However, the presence of high net losses could affect future equity levels if not addressed.
Cash Flow
60
Neutral
The company has improved its cash flow position, transitioning from negative free cash flow in earlier years to positive free cash flow in 2025. Operating cash flow has also turned positive, which is a positive sign for operational efficiency. However, the ratio of operating cash flow to net income is low due to significant net losses.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue323.90M961.06M269.49M229.07M100.10M205.97M
Gross Profit264.84M811.03M217.49M206.94M84.86M181.78M
EBITDA-632.43M-99.06M-723.85M-738.34M-726.86M-621.70M
Net Income-667.95M-140.81M-763.75M-778.82M-767.72M-659.24M
Balance Sheet
Total Assets5.08B5.42B3.82B4.33B4.72B2.05B
Cash, Cash Equivalents and Short-Term Investments3.45B3.21B2.35B2.71B3.28B1.25B
Total Debt813.00M766.78M933.30M1.09B1.25B1.41B
Total Liabilities2.10B2.21B1.44B1.58B1.64B1.82B
Stockholders Equity2.97B3.21B2.38B2.75B3.08B230.72M
Cash Flow
Free Cash Flow0.00136.50M-887.82M-857.00M-1.13B-795.25M
Operating Cash Flow0.00140.41M-876.84M-827.67M-1.08B-772.81M
Investing Cash Flow0.00287.58M-9.01M-29.93M-350.56M-22.86M
Financing Cash Flow0.00725.78M228.35M291.82M3.83B-332.40M

STELLA PHARMA CORPORATION Technical Analysis

Technical Analysis Sentiment
Positive
Last Price385.00
Price Trends
50DMA
363.64
Positive
100DMA
383.69
Positive
200DMA
446.44
Negative
Market Momentum
MACD
6.86
Positive
RSI
53.57
Neutral
STOCH
32.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4888, the sentiment is Positive. The current price of 385 is below the 20-day moving average (MA) of 397.55, above the 50-day MA of 363.64, and below the 200-day MA of 446.44, indicating a neutral trend. The MACD of 6.86 indicates Positive momentum. The RSI at 53.57 is Neutral, neither overbought nor oversold. The STOCH value of 32.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4888.

STELLA PHARMA CORPORATION Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
¥13.22B284.55
0.75%-13.57%-106.11%
55
Neutral
¥13.10B
256.62%81.71%
54
Neutral
¥12.89B
57.13%-66.39%
52
Neutral
$7.45B0.27-61.87%2.30%16.62%1.04%
48
Neutral
¥9.73B
14.41%27.42%
47
Neutral
¥18.77B
-100.00%-1079.89%
43
Neutral
¥15.20B
11.93%15.04%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4888
STELLA PHARMA CORPORATION
396.00
-19.00
-4.58%
JP:4579
RaQualia Pharma Inc.
534.00
-66.00
-11.00%
JP:4583
Chiome Bioscience Inc.
143.00
23.00
19.17%
JP:4588
Oncolys BioPharma, Inc.
615.00
36.00
6.22%
JP:4599
StemRIM Inc.
301.00
-159.00
-34.57%
JP:4880
CellSource Co., Ltd.
681.00
-751.94
-52.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 09, 2025